BioAge Labs (NASDAQ:BIOA) Hits New 1-Year High – Time to Buy?

BioAge Labs, Inc. (NASDAQ:BIOA) reached a new 52-week high during trading on Wednesday . The company traded as high as $14.21 and last traded at $14.2380, with a volume of 57180 shares trading hands. The stock had previously closed at $13.21.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BIOA. Wall Street Zen raised shares of BioAge Labs from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Finally, Citigroup boosted their price objective on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $15.00.

BioAge Labs Stock Performance

The firm has a market cap of $513.37 million, a PE ratio of -9.45 and a beta of 1.74. The business’s 50 day simple moving average is $9.03.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $2.05 million during the quarter.

Insider Transactions at BioAge Labs

In other BioAge Labs news, insider Paul D. Rubin sold 68,897 shares of BioAge Labs stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $10.19, for a total value of $702,060.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.82% of the stock is owned by corporate insiders.

Institutional Trading of BioAge Labs

Several hedge funds have recently made changes to their positions in BIOA. Public Employees Retirement System of Ohio acquired a new position in BioAge Labs during the 2nd quarter valued at approximately $57,000. Geode Capital Management LLC increased its position in BioAge Labs by 60.8% in the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after buying an additional 171,426 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in BioAge Labs in the second quarter valued at $27,000. Intech Investment Management LLC acquired a new position in shares of BioAge Labs during the second quarter valued at $60,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of BioAge Labs during the second quarter worth about $206,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.